Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Provides Update on the Cronobacter Prevention StrategyCFSAN Constituent Updates FDA Provides Update on the Cronobacter Prevention Strategy
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintConstituent Update

September 20, 2023

The U.S. Food and Drug Administration (FDA) is providing an update on its work to advance its strategy to help prevent *Cronobacter sakazakii* illnesses associated with consumption of powdered infant formula.

A draft outline of the prevention strategy was first released in November 2022 in response to the infant formula shortage earlier that year following a large-scall recall and temporary shutdown of one of the nation’s largest infant formula manufacturing facilities prompted by safety concerns at the facility. At the time, the FDA committed to using the strategy to guide its work to enhance the safety of powdered infant including through engagements with the infant formula industry and other stakeholders. These engagements further supported the strategy that was laid out, and at this time the strategy will continue forward without further actions being added. The FDA may add additional actions over time as more information is learned.

Today, the agency is providing an update on the significant actions that have been taken to advance the goals of the strategy, including:

Continuous collaboration with industry, coalitions, academia, and consumer groups to better understand and explore ways to enhance the safety of powdered infant formula.
	Issuance of a letter to the powdered infant formula industry to share current safety information and a call to industry to take prompt action to improve processes related to the safe production of powdered infant formula.
	Initiation of hiring to establish a dedicated cadre of investigators to conduct infant formula inspections.
	Initiation of hiring of staff to support the new Office of Critical Foods.
	Supporting the Council of State and Territorial Epidemiologists (CSTE) position on elevating *Cronobacter* to a nationally notifiable disease, which was successfully adopted by the CSTE on June 29, 2023.
	Updating and reorganizing infant formula related materials on FDA.gov to provide both consumers and industry with more accessible information, including:
	Infant Formula
		*Cronobacter sakazakii*
	Initiating work with the National Advisory Committee on Microbiological Criteria for Foods (NACMCF) to address knowledge gaps regarding *Cronobacter sakazakii*.The updated prevention strategy webpage includes a full list of actions that have been taken to date.

While these actions are specific to work guided by the prevention strategy, the FDA has continued to undertake additional steps to enhance its regulatory oversight of the infant formula industry. This includes the recent issuance of three warning letters to infant formula firms in August 2023. The letters reinforce the importance of instituting and maintaining appropriate corrective actions when pathogens are detected to ensure compliance with the FDA’s laws and regulations.

In addition, the FDA is continuing to advance work to strengthen the resiliency of the infant formula market, including through the issuance of an Immediate National Strategy, initiating work with the National Academies of Sciences, Engineering, and Medicine to help inform long term plans for strengthening the infant formula market and through ongoing work to enhance and expedite infant formula reviews. Infant formula firms are also now required to develop, maintain and implement, as appropriate, risk management plans to identify and evaluate risks to the supply of the critical food, such as infant formula, and ways to mitigate such risks. This is a new requirement mandated by Congress in the Food and Drug Omnibus Reform Act of 2022.

The FDA is committed to continuing its work to strengthen the safety, resiliency, and oversight of the infant formula industry and will continue to provide updates as they become available.

                                                                                  Content current as of:
      09/20/2023
              
              
Regulated Product(s)
		 Food & Beverages
			  			     			  						              
			
			
			
			
			
						  Infant Formula & FoodsCFSAN Constituent Updates
 Subscribe to CFSAN Constituent Updates
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop